| Date of authorisation by the Extraordinary General Meeting | 30.06.2020 | 30.06.2020 | 21.04.2022 | 21.04.2023 |
|---|---|---|---|---|
| Date of grant by the Board of Directors | Date of grant by the Board of Directors 30.06.202014.10.2020 |
Date of grant by the Board of Directors 30.06.202007.10.2021 |
Date of grant by the Board of Directors 21.04.202213.10.2022 |
Date of grant by the Board of Directors 21.04.202312.10.2023 |
| Total number of shares conditionally granted | Total number of shares conditionally granted 30.06.2020713,660 |
Total number of shares conditionally granted 30.06.2020588,750 |
Total number of shares conditionally granted 21.04.2022700,000 |
Total number of shares conditionally granted 21.04.2023650,580 |
| Of which the 10 employees other than directors and corporate officers granted the largest number of shares(1) | Of which the 10 employees other than directors and corporate officers granted the largest number of shares (1)30.06.2020111,250 |
Of which the 10 employees other than directors and corporate officers granted the largest number of shares (1)30.06.202072,400 |
Of which the 10 employees other than directors and corporate officers granted the largest number of shares (1)21.04.202278,400 |
Of which the 10 employees other than directors and corporate officers granted the largest number of shares (1)21.04.202370,650 |
| Number of beneficiaries | Number of beneficiaries 30.06.20202,208 |
Number of beneficiaries 30.06.20202,408 |
Number of beneficiaries 21.04.20222,647 |
Number of beneficiaries 21.04.20232,763 |
| Performance conditions | Performance conditions 30.06.2020
|
Performance conditions 30.06.2020
|
||
| Date of vesting | Date of vesting 30.06.202015.10.2024 |
Date of vesting 30.06.202008.10.2025 |
Date of vesting 21.04.202214.10.2026 |
Date of vesting 21.04.202313.10.2027 |
| End of lock-in period | End of lock-in period 30.06.2020N/A |
End of lock-in period 30.06.2020N/A |
End of lock-in period 21.04.2022N/A |
End of lock-in period 21.04.2023N/A |
At its meeting on 8 February 2024, the Board of Directors found that 100% of the performance conditions were achieved during the three years taken into consideration by the ACAs plan of 14 October 2020, namely 2021, 2022 and 2023. Accordingly, the beneficiaries who fulfil the conditions
of the plan on 14 October 2024 and, in particular, that relating to the condition of presence in the Company, will receive 100% of the shares that were granted to them.
For the record, Mr Jean-Paul Agon, Chairman and Chief Executive Officer at the time of the grant of shares, told the Board of Directors that he did not wish to be granted ACAs for the 2020 financial year. He did not benefit from any grant of shares under the Plan of 14 October 2020.
| ACAs plan of 14 October 2020 | 2021 | 2022 | 2023 | Arithmetic average of performances for financial years 2021, 2022 and 2023 |
|---|---|---|---|---|
| 50% growth in like-for-like sales compared to a panel of competitors*The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Kenvue (formerly Johnson & Johnson), Henkel, LVMH, Kao and Coty. | 50% growth in like-for-like sales compared to a panel of competitors *The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Kenvue (formerly Johnson & Johnson), Henkel, LVMH, Kao and Coty.2021+6.9 points (+16.1%/+9.2%) |
50% growth in like-for-like sales compared to a panel of competitors *The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Kenvue (formerly Johnson & Johnson), Henkel, LVMH, Kao and Coty.2022+7.3 points (+10.9%/+3.6%) |
50% growth in like-for-like sales compared to a panel of competitors *The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Kenvue (formerly Johnson & Johnson), Henkel, LVMH, Kao and Coty.2023+5.8 points (+11%/+5.2%) |
50% growth in like-for-like sales compared to a panel of competitors *The panel consists of the following companies: Unilever, Procter & Gamble, Estée Lauder, Shiseido, Beiersdorf, Kenvue (formerly Johnson & Johnson), Henkel, LVMH, Kao and Coty.Arithmetic averageof performances for financial years 2021, 2022 and 2023+6.7 % |
| 50% variation in the Group’s operating profit | 50% variation in the Group’s operating profit 2021+18.30% (5,209.0/6,160.3) |
50% variation in the Group’s operating profit 2022+21.00% (6,160.3/7,456.9) |
50% variation in the Group’s operating profit 2023+ 9.20% (7,456.9/8,143.3) |
50% variation in the Group’s operating profit Arithmetic averageof performances for financial years 2021, 2022 and 2023+16.2 % |
